Wegovy pill offers 'significant' weight reduction, Novo Nordisk says, as oral obesity drug race intensifies
1. Novo Nordisk's oral obesity pill shows 16.6% weight loss effect. 2. FDA decision on pill expected in Q4 2025, boosting production in the U.S. 3. Competitor Eli Lilly's pill could receive fast-tracked FDA approval soon. 4. Novo maintains focus on diabetes and obesity amid plans to downsize workforce. 5. Semaglutide pill aims to match injection's efficacy and safety.